|
|
Hypertension and Diabetic Kidney Disease - Prevalence, current treatment and future optionsPublished by: Datamonitor Published: Oct. 25, 2005 - 71 Pages Table of ContentsTABLE OF CONTENTS EXECUTIVE SUMMARY 5 Introduction 5 Scope and coverage of the Brief 5 Key findings about the the topic 6 EPIDEMIOLOGY 7 Definition 7 Etiology of diabetic nephropathy 9 The role of hypertension in diabetic nephropathy 9 Prevalence of hypertensive patients with diabetes 10 Prevalence of hypertensive patients with diabetes 11 Prevalence of nephropathy in type 2 diabetics 13 Progression of diabetic nephropathy in type 2 patients. 15 The growing burden of ESRD on healthcare systems 17 Key factors influencing the ESRD market 19 TREATMENT OF DIABETIC NEPHROPATHY 25 Glucose control in diabetic nephropathy 25 Importance of blood pressure control 25 Pharmacological strategy: the role of the renin-angiotensin system 30 Benefits of ACE inhibition 38 Benefits of angiotensin II receptor blockade 43 FUTURE TREATMENT OF DIABETIC NEPHROPATHY 50 Potential of the ACE/ARB combination 50 Renin inhibition: what are the therapeutic opportunities? 52 New compounds should target the underlying disease 53 New approaches for diabetic microvascular complications 54 Potential treatments for diabetic nephropathy 57 Conclusion 65 APPENDIX 66 Bibliography 66 Disclaimer 70 AbstractIntroductionThe increase in diabetic kidney disease is a worldwide problem. Current treatment centers on antihypertensives inhibitors for the renin-angiotensin system and merely retards the decline of renal function. A large unmet need thus exists for therapies that fully halt disease progression or provide curative benefit Scope The prevalence and progression of diabetic nephropathy in the seven major markets is evaluated The foremost pharmacological strategies for the treatment of diabetic nephropathy are reviewed The current status of angiotensin II receptor blockade as first line therapy in the treatment of diabetic nephropathy is discussed An overview is given of the drugs in development for the treatment of diabetic nephropathy Highlights The necessity for aggressive blood pressure control is undisputed in the medical community, but the therapeutic focus is now extending to end-organ protection as a treatment goal of equal importance to BP reduction. Thus, commercial performance of both ACE inhibitors and ARBs is dependent on renoprotective benefits beyond blood pressure control The pipeline for developmental drugs targeting the cause of diabetic kidney disease is dominated by endothelin receptor antagonists and advanced glycosylation end product inhibitors. The commercial potential for successful new agents is substantial as existing therapies do not halt the progression of diabetic nephropathy to end stage renal disease Proximal blockade of the renin-angiotensin system (RAS) through renin inhibition offers greater treatment opportunities than distal inhibition via angiotensin II receptor blockade. Recent basic and clinical research supports the strong theoretical appeal of renin inhibition as the most promising pharmacological strategy in the short-to-medium term Reasons to Purchase Explore the growing burden of ESRD on healthcare systems through data on the prevalence and progression of diabetic nephropathy Assess the potential of current treatment options in the diabetic nephropathy arena Identify novel R&D compounds in the diabetic nephropathy pipeline Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||